» Articles » PMID: 32060938

Susceptibility of Rat Steatotic Liver to Ischemia-Reperfusion Is Treatable With Liver-Selective Matrix Metalloproteinase Inhibition

Overview
Journal Hepatology
Specialty Gastroenterology
Date 2020 Feb 16
PMID 32060938
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: This study examined whether enhanced susceptibility of steatotic liver to ischemia-reperfusion (I/R) injury is due to impaired recruitment of bone marrow (BM) progenitors of liver sinusoidal endothelial cells (LSECs, also called sinusoidal endothelial cell progenitor cells [sprocs]) with diminished repair of injured LSECs and whether restoring signaling to recruit BM sprocs reduces I/R injury.

Approach And Results: Hepatic vessels were clamped for 1 hour in rats fed a high-fat, high-fructose (HFHF) diet for 5, 10, or 15 weeks. Matrix metalloproteinase 9 (MMP-9) antisense oligonucleotides (ASO) or an MMP inhibitor were used to induce liver-selective MMP-9 inhibition. HFHF rats had mild, moderate, and severe steatosis, respectively, at 5, 10, and 15 weeks. I/R injury was enhanced in HFHF rats; this was accompanied by complete absence of hepatic vascular endothelial growth factor (VEGF)-stromal cell-derived factor 1 (sdf1) signaling, leading to lack of BM sproc recruitment. Liver-selective MMP-9 inhibition to protect against proteolytic cleavage of hepatic VEGF using either MMP-9 ASO or intraportal MMP inhibitor in 5-week and 10-week HFHF rats enhanced hepatic VEGF-sdf1 signaling, increased BM sproc recruitment, and reduced alanine aminotransferase (ALT) by 92% and 77% at 5 weeks and by 80% and 64% at 10 weeks of the HFHF diet, respectively. After I/R injury in 15-week HFHF rats, the MMP inhibitor reduced active MMP-9 expression by 97%, ameliorated histologic evidence of injury, and reduced ALT by 58%, which is comparable to control rats sustaining I/R injury. Rescue therapy with intraportal MMP inhibitor, given after ischemia, in the 5-week HFHF rat reduced ALT by 71% and reduced necrosis.

Conclusions: Lack of signaling to recruit BM sprocs that repair injured LSECs renders steatotic liver more susceptible to I/R injury. Liver-selective MMP-9 inhibition enhances VEGF-sdf1 signaling and recruitment of BM sprocs, which markedly protects against I/R injury, even in severely steatotic rats.

Citing Articles

A Multidrug Donor Preconditioning Improves Steatotic Rat Liver Allograft Function and Recipient Survival After Transplantation.

Xu M, Alwahsh S, Kim M, Kollmar O Transpl Int. 2024; 37:13557.

PMID: 39726675 PMC: 11671227. DOI: 10.3389/ti.2024.13557.


Current status and perspective on molecular targets and therapeutic intervention strategy in hepatic ischemia-reperfusion injury.

Liu J, Luo R, Zhang Y, Li X Clin Mol Hepatol. 2024; 30(4):585-619.

PMID: 38946464 PMC: 11540405. DOI: 10.3350/cmh.2024.0222.


SENP1 attenuates hypoxia‑reoxygenation injury in liver sinusoid endothelial cells by relying on the HIF‑1α signaling pathway.

Qing Z, Luo Q, Duan J, Lin J, Huang H, Yang S Mol Med Rep. 2024; 29(4).

PMID: 38426545 PMC: 10926105. DOI: 10.3892/mmr.2024.13188.


Mesenchymal stem cells and ferroptosis: Clinical opportunities and challenges.

Cui M, Chen F, Shao L, Wei C, Zhang W, Sun W Heliyon. 2024; 10(3):e25251.

PMID: 38356500 PMC: 10864896. DOI: 10.1016/j.heliyon.2024.e25251.


Ferroptosis: a promising candidate for exosome-mediated regulation in different diseases.

Liu L, Ye Y, Lin R, Liu T, Wang S, Feng Z Cell Commun Signal. 2024; 22(1):6.

PMID: 38166927 PMC: 11057189. DOI: 10.1186/s12964-023-01369-w.


References
1.
McKeown S, Richter A, OKane C, McAuley D, Thickett D . MMP expression and abnormal lung permeability are important determinants of outcome in IPF. Eur Respir J. 2008; 33(1):77-84. DOI: 10.1183/09031936.00060708. View

2.
Strasberg S, Howard T, Molmenti E, Hertl M . Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation. Hepatology. 1994; 20(4 Pt 1):829-38. DOI: 10.1002/hep.1840200410. View

3.
Brown P . Clinical studies with matrix metalloproteinase inhibitors. APMIS. 1999; 107(1):174-80. DOI: 10.1111/j.1699-0463.1999.tb01541.x. View

4.
Wang X, Maretti-Mira A, Wang L, DeLeve L . Liver-Selective MMP-9 Inhibition in the Rat Eliminates Ischemia-Reperfusion Injury and Accelerates Liver Regeneration. Hepatology. 2018; 69(1):314-328. PMC: 6325019. DOI: 10.1002/hep.30169. View

5.
Brown P . Ongoing trials with matrix metalloproteinase inhibitors. Expert Opin Investig Drugs. 2000; 9(9):2167-77. DOI: 10.1517/13543784.9.9.2167. View